Last reviewed · How we verify
BKM-120 Bevacizumab
At a glance
| Generic name | BKM-120 Bevacizumab |
|---|---|
| Also known as | Avastin |
| Sponsor | Toni Choueiri, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme (PHASE1, PHASE2)
- Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BKM-120 Bevacizumab CI brief — competitive landscape report
- BKM-120 Bevacizumab updates RSS · CI watch RSS
- Toni Choueiri, MD portfolio CI